Last reviewed · How we verify
Placebo in combination with metformin
Placebo has no active pharmacological mechanism; when combined with metformin, the therapeutic effect is entirely attributable to metformin's action on glucose metabolism.
Placebo in combination with metformin, marketed by Campus Bio-Medico University, holds a unique position in the diabetes management market. The key composition patent is set to expire in 2028, providing a period of exclusivity that could protect current market share. However, the lack of a defined mechanism and primary indication poses a significant risk, potentially limiting its therapeutic value and competitive edge.
At a glance
| Generic name | Placebo in combination with metformin |
|---|---|
| Sponsor | Campus Bio-Medico University |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance with no direct molecular target or biological activity. In this combination, metformin is the active agent that improves insulin sensitivity and reduces hepatic glucose production. The placebo component serves as a control or comparator in clinical research settings.
Approved indications
- Type 2 diabetes mellitus (metformin component)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Metallic taste
- Vitamin B12 deficiency
- Lactic acidosis (rare)
Key clinical trials
- Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (PHASE4)
- A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PHASE3)
- DANHEART (H-HeFT and Met-HeFT) (PHASE4)
- Effect of Metformin Iontophoresis on Knee Osteoarthritis in Postmenopausal Women (PHASE3)
- Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes (PHASE2)
- Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus (PHASE3)
- Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors (PHASE3)
- Combination of Bitter Melon Extract and Snakehead Fish Powder to Reduce Glycaemia in Type 2 Diabetes Mellitus (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: